Abstract
Objective: Anti-VEGF and anti-DLL4 have both demonstrated single-agent activity in ovarian cancer. Navicixizumab is an anti-DLL4/VEGF IgG2 bispecific monoclonal antibody that had a response rate of 25% (3/12) in heavily pretreated ovarian cancer patients in an earlier single-agent phase 1a trial. This is an ongoing phase 1b study designed to assess the safety and efficacy of paclitaxel and navicixizumab in platinum-resistant ovarian cancer patients who received at least 3 prior therapies and/or bevacizumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
